Skip to main content

Advertisement

Log in

Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Modelling is an important applied tool in drug discovery and development for the prediction and interpretation of drug pharmacokinetics. Preclinical information is used to decide whether a compound will be taken forwards and its pharmacokinetics investigated in human. After proceeding to human little to no use is made of these often very rich data. We suggest a method where the preclinical data are integrated into a whole body physiologically based pharmacokinetic (WBPBPK) model and this model is then used for estimating population PK parameters in human. This approach offers a continuous flow of information from preclinical to clinical studies without the need for different models or model reduction. Additionally, predictions are based upon single parameter values, but making realistic predictions involves incorporating the various sources of variability and uncertainty. Currently, WBPBPK modelling is undertaken as a two-stage process: (i) estimation (optimisation) of drug-dependent parameters by either least squares regression or maximum likelihood and (ii) accounting for the existing parameter variability and uncertainty by stochastic simulation. To address these issues a general Bayesian approach using WinBUGS for estimation of drug-dependent parameters in WBPBPK models is described. Initially applied to data in rat, this approach is further adopted for extrapolation to human, which allows retention of some parameters and updating others with the available human data. While the issues surrounding the incorporation of uncertainty and variability within prediction have been explored within WBPBPK modeling methodology they have equal application to other areas of pharmacokinetics, as well as to pharmacodynamics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andersen M., Clewell H., Gargas M., Smith F., Reitz R. (1987). Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87:187–205

    Article  Google Scholar 

  2. Banks H., Potter L. (2002). Model predictions and comparisons for three toxicokinetics models for the systemic transport of trichloroethylene. Math. Comput. Model. 35:1007–1032

    Article  Google Scholar 

  3. Bois F., Zeise L., Tozer T. (1990). Precision and sensitivity of pharmacokinetic models for cancer risk assesment: tetrachlorethylene in mice, rats and humans. Toxicol. Appl. Pharmacol. 102:300–315

    Article  PubMed  CAS  Google Scholar 

  4. Woodruff T.J., Bois F.Y. (1993). Optimisation issues in physiological toxicokinetic modelling: a case study with benzene. Toxicol Lett. 69:181–196

    Article  PubMed  CAS  Google Scholar 

  5. Wakefield J.C., Smith A.F, Racine-Poon A, Gelfand A. (1994). Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Appl. Stat.-J Roy St. C 43:201–221

    Google Scholar 

  6. Gueorguieva I., Nestorov I., Rowland M. (2006). Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J. Pharmacokinet. Phar. 33:1–27

    Article  CAS  Google Scholar 

  7. Sheiner L.B. (1984). The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab. Rev. 15:153–171

    Article  PubMed  CAS  Google Scholar 

  8. Wakefield J.C. (1996). Bayesian analysis of population pharmacokinetic models. J. Am. Stat. Assoc. 91:62–75

    Article  Google Scholar 

  9. Gelman A., Bois F., Jiang J. (1996). Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91:1400–1412

    Article  Google Scholar 

  10. Bois F. (2000). Statistical analysis of clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Persp. 108:307–316

    CAS  Google Scholar 

  11. Jonsson F., Johanson G. (2001). Bayesian estimation of variability in adipose tissue blood flow in man by physiologically base pharmacokinetic modelling of inhalation exposure to toluene. Toxicology 157:177–193

    Article  PubMed  CAS  Google Scholar 

  12. Lunn D.J., Best N., Thomas A., Wakefield J., Spiegelhalter D. Bayesian analysis of population PK/PD models: general concepts and software. J. Pharmacokinet. Pharmacodyn. 29(3):271–307.

  13. Best N.G., Cowles M.K., Vines S.K. (1995) CODA Manual Version 0.30. MRC Biostatistics Unit, Cambridge, UK

    Google Scholar 

  14. Gueorguieva I., Nestorov I., Rowland M. (2004). Fuzzy simulations of pharmacokinetic models: case study of whole body physiologically based model of diazepam. J. Pharmacokinet. Phar. 31(3):185–212

    Article  CAS  Google Scholar 

  15. Igari Y., Sugiyama Y., Sawada Y., Iga T., Hanano M. (1983). Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model. J. Pharmacokinet. Biop. 11:577–593

    Article  CAS  Google Scholar 

  16. Kuwahira I, Gonzalez I., Heisler N., Piper J. (1993). Regional blood flows in conscious resting rats determined by microsphere distribution. J. Appl. Physiol. 74:203–210

    PubMed  CAS  Google Scholar 

  17. Brown R.P., Delp M.D., Beliles R.P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13(4):406–484

    Google Scholar 

  18. Poulin P., Thiel F.-P. (2002). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91(1):129–156

    Article  PubMed  CAS  Google Scholar 

  19. Greenblatt D.J., Allen M.D., Harmatz J.S., Shader R.I. (1980). Diazepam disposition determinants. Clin. Pharmacol. Ther. 27(3):301–312

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ivelina Gueorguieva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gueorguieva, I., Aarons, L. & Rowland, M. Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs. J Pharmacokinet Pharmacodyn 33, 571–594 (2006). https://doi.org/10.1007/s10928-006-9023-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-006-9023-3

Keywords

Navigation